2024
Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease
Talasaz A, Sadeghipour P, Ortega-Paz L, Kakavand H, Aghakouchakzadeh M, Beavers C, Fanikos J, Eikelboom J, Siegal D, Monreal M, Jimenez D, Vaduganathan M, Castellucci L, Cuker A, Barnes G, Connors J, Secemsky E, Van Tassell B, De Caterina R, Kurlander J, Aminian A, Piazza G, Goldhaber S, Moores L, Middeldorp S, Kirtane A, Elkind M, Angiolillo D, Konstantinides S, Lip G, Stone G, Cushman M, Krumholz H, Mehran R, Bhatt D, Bikdeli B. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. Nature Reviews Cardiology 2024, 21: 574-592. PMID: 38509244, DOI: 10.1038/s41569-024-01003-3.Peer-Reviewed Original ResearchRisk of gastrointestinal bleedingGastrointestinal bleedingAntithrombotic therapyHigh risk of gastrointestinal bleedingIncreased risk of bleedingRisk of bleedingGastrointestinal diseasesEfficacy of antithrombotic agentsAntithrombotic regimensConcomitant medicationsRisk stratificationClinical evidenceGastrointestinal comorbiditiesMultidisciplinary discussionAntithrombotic drugsAntithrombotic agentsIncreased riskHigh riskPatientsGastrointestinal disordersCardiovascular diseaseTherapyBleedingDiseaseMedical societies
2023
MULTINATIONAL PATTERNS OF SECOND-LINE ANTI-HYPERGLYCEMIC DRUG INITIATION IN ESTABLISHED CARDIOVASCULAR DISEASE: A FEDERATED PHARMACOEPIDEMIOLOGIC EVALUATION IN LEGEND-T2DM
Khera R, Dhingra L, Li K, Aminorroaya A, Zhou J, Arshad F, Bu F, Dorr D, Falconer T, French T, Lau W, Lu Y, Man K, Matheny M, Minty E, Nishimura A, Ostropolets A, Seager S, Y.F. W, Yang J, Yin C, Hripcsak G, Krumholz H. MULTINATIONAL PATTERNS OF SECOND-LINE ANTI-HYPERGLYCEMIC DRUG INITIATION IN ESTABLISHED CARDIOVASCULAR DISEASE: A FEDERATED PHARMACOEPIDEMIOLOGIC EVALUATION IN LEGEND-T2DM. Journal Of The American College Of Cardiology 2023, 81: 1646. DOI: 10.1016/s0735-1097(23)02090-9.Peer-Reviewed Original ResearchDrug initiationDisease
2022
Clinical decision support in cardiovascular medicine
Lu Y, Melnick ER, Krumholz HM. Clinical decision support in cardiovascular medicine. The BMJ 2022, 377: e059818. PMID: 35613721, DOI: 10.1136/bmj-2020-059818.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseCardiovascular careEffectiveness of CDSRisk factor modificationClinical decision support toolQuality of careClinical decision supportClinical outcomesFactor modificationHealth information technologyClinical practicePatient careDiseaseCardiovascular medicineCDS effectivenessCareEffectiveness of deliveryMissed opportunityTreatmentFailureProper evidenceHealthcare processesMedicineEvidencePrevention
2021
Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States
Valero-Elizondo J, Chouairi F, Khera R, Grandhi GR, Saxena A, Warraich HJ, Virani SS, Desai NR, Sasangohar F, Krumholz HM, Esnaola NF, Nasir K. Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States. JACC CardioOncology 2021, 3: 236-246. PMID: 34396329, PMCID: PMC8352280, DOI: 10.1016/j.jaccao.2021.02.006.Peer-Reviewed Original ResearchCost-related medication nonadherenceFinancial toxicityMedication nonadherenceNational Health Interview SurveyAtherosclerotic cardiovascular diseaseMedical billsHealth Interview SurveyCancer careASCVDCardiovascular diseaseHigh burdenHigher oddsElderly populationCancerInterview SurveyFood insecurityCareNonadherenceSignificant proportionAdultsToxicityHigh financial distressPatientsPrevalenceDisease
2020
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group E. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2020, 75: 2950-2973. PMID: 32311448, PMCID: PMC7164881, DOI: 10.1016/j.jacc.2020.04.031.Peer-Reviewed Original ResearchConceptsAntithrombotic therapyThrombotic diseaseCOVID-19Outcomes of patientsViral respiratory illnessEndothelial dysfunctionArterial thrombosisThromboembolic diseaseExcessive inflammationRespiratory illnessLaboratory monitoringJACC StateArterial circulationPlatelet activationPatientsCoronavirus diseaseDiseaseTherapyCOVID-19 pandemicPreventionCurrent understandingThromboticThrombosisInflammationDysfunction
2019
Absence of Coronary Artery Calcification in Middle-Aged Familial Hypercholesterolemia Patients Without Atherosclerotic Cardiovascular Disease
Mszar R, Grandhi GR, Valero-Elizondo J, Virani SS, Blankstein R, Blaha M, Mata P, Miname MH, Al Rasadi K, Krumholz HM, Santos RD, Nasir K. Absence of Coronary Artery Calcification in Middle-Aged Familial Hypercholesterolemia Patients Without Atherosclerotic Cardiovascular Disease. JACC Cardiovascular Imaging 2019, 13: 1090-1092. PMID: 31843585, DOI: 10.1016/j.jcmg.2019.11.001.Peer-Reviewed Original ResearchPulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015
Bikdeli B, Wang Y, Jimenez D, Parikh SA, Monreal M, Goldhaber SZ, Krumholz HM. Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. JAMA 2019, 322: 574-576. PMID: 31408124, PMCID: PMC6692667, DOI: 10.1001/jama.2019.8594.Peer-Reviewed Original Research
2018
Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease
Emdin CA, Khera AV, Chaffin M, Klarin D, Natarajan P, Aragam K, Haas M, Bick A, Zekavat SM, Nomura A, Ardissino D, Wilson JG, Schunkert H, McPherson R, Watkins H, Elosua R, Bown MJ, Samani NJ, Baber U, Erdmann J, Gupta N, Danesh J, Chasman D, Ridker P, Denny J, Bastarache L, Lichtman JH, D’Onofrio G, Mattera J, Spertus JA, Sheu W, Taylor KD, Psaty BM, Rich SS, Post W, Rotter JI, Chen YI, Krumholz H, Saleheen D, Gabriel S, Kathiresan S. Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. Nature Communications 2018, 9: 1613. PMID: 29691411, PMCID: PMC5915445, DOI: 10.1038/s41467-018-03911-8.Peer-Reviewed Original ResearchConceptsPLOF variantsProtein-coding genetic variantsFunction variantsCoronary artery diseaseBody fat distributionType 2 diabetesEssential splice siteProtein functionEffector transcriptsUK Biobank participantsIdentifies variantsStop codonMetabolic traitsArtery diseaseSplice siteAllergic diseasesAssociation analysisCardiometabolic diseasesAdditional diseaseFat distributionGenetic variantsBiobank participantsDiseaseBiological effectsVariantsReply to Soo Hoo and Esquinas: Risk Trajectories of Readmission and Death in the First Year after Hospitalization for Chronic Obstructive Pulmonary Disease: Don’t Shortchange Noninvasive Ventilation
Lindenauer PK, Dharmarajan K, Krumholz HM. Reply to Soo Hoo and Esquinas: Risk Trajectories of Readmission and Death in the First Year after Hospitalization for Chronic Obstructive Pulmonary Disease: Don’t Shortchange Noninvasive Ventilation. American Journal Of Respiratory And Critical Care Medicine 2018, 198: 283-284. PMID: 29566340, PMCID: PMC6058983, DOI: 10.1164/rccm.201803-0426le.Peer-Reviewed Original ResearchComparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study
Wallach JD, Ciani O, Pease AM, Gonsalves GS, Krumholz HM, Taylor RS, Ross JS. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study. BMC Medicine 2018, 16: 45. PMID: 29562926, PMCID: PMC5863466, DOI: 10.1186/s12916-018-1023-9.Peer-Reviewed Original ResearchConceptsPostapproval trialsPivotal trialsActual clinical effectSurrogate markerTrial endpointsLarge treatment effectsPrimary endpointNovel therapeuticsNovel drugsTreatment effectsFDA approvalPatient-relevant outcomesMeta-epidemiological studyStandardized mean differenceTreatment effect sizeClinical effectsResultsBetween 2005Odds ratioDrug trialsSame indicationDrug AdministrationEvidence of differencesMean differenceU.S. FoodDisease
2017
The primary health-care system in China
Li X, Lu J, Hu S, Cheng K, De Maeseneer J, Meng Q, Mossialos E, Xu DR, Yip W, Zhang H, Krumholz HM, Jiang L, Hu S. The primary health-care system in China. The Lancet 2017, 390: 2584-2594. PMID: 29231837, DOI: 10.1016/s0140-6736(17)33109-4.Peer-Reviewed Original ResearchConceptsPrimary health care systemHealth care systemChronic non-communicable diseasesEvidence-based performance indicatorsNon-communicable diseasesEveryday clinical practiceQuality of careHealth information technology systemsRisk factorsClinical practiceCare deliveryVillage doctorsHealth care reformInadequate educationCost savingsWorld populationPopulationPrevalenceDiseaseAssociation of the FDA Amendment Act with trial registration, publication, and outcome reporting
Phillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials 2017, 18: 333. PMID: 28720112, PMCID: PMC5516301, DOI: 10.1186/s13063-017-2068-3.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseTRIAL REGISTRATIONFDA approvalNew drugsClinical trial registrationFDA Amendments ActDrug Administration Amendments ActAccessible trial registryClinical trial publicationsTrials RegistryResultsBetween 2005Efficacy trialsFDA reviewersTrial publicationsOutcome reportingMedical literatureReviewer interpretationsTrialsReporting of findingsDiseaseFDA documentsDrugsDiabetesFDAAAReviewersPostapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Pease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. The BMJ 2017, 357: j1680. PMID: 28468750, PMCID: PMC5421452, DOI: 10.1136/bmj.j1680.Peer-Reviewed Original ResearchConceptsSingle pivotal trialPivotal trialsPostapproval studiesSurrogate markerPrimary endpointNovel drugsClinical outcomesClinical studiesLimited evidenceSystematic reviewDouble-blind studyMedian total numberClinical evidenceSuperior efficacyBlind studyDrug AdministrationOriginal FDATrial approvalDiseaseTrialsDrugsFDAEndpointEfficacyMarkersYoung Women With Acute Myocardial Infarction
Dreyer RP, Sciria C, Spatz ES, Safdar B, D'Onofrio G, Krumholz HM. Young Women With Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2017, 10: e003480. PMID: 28228455, PMCID: PMC5502480, DOI: 10.1161/circoutcomes.116.003480.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionYoung womenMyocardial infarctionManagement of AMIPost-AMI periodContinuum of careCoronary diseaseAged menHigh riskWorse recoveryWomenInfarctionHighlight gapsRecent studiesDifferent mechanismsMorbidityHospitalMortalityEpidemiologyPublic awarenessDiseaseDiagnosisCare
2015
Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system
Jiang L, Krumholz HM, Li X, Li J, Hu S. Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system. The Lancet 2015, 386: 1493-1505. PMID: 26466053, PMCID: PMC5323019, DOI: 10.1016/s0140-6736(15)00343-8.Peer-Reviewed Original ResearchOlder Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods
Feinstein AJ, Long J, Soulos PR, Ma X, Herrin J, Frick KD, Chagpar AB, Krumholz HM, Yu JB, Ross JS, Gross CP. Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Affairs 2015, 34: 592-600. PMID: 25847641, DOI: 10.1377/hlthaff.2014.1119.Peer-Reviewed Original ResearchConceptsStage II diseaseStage III diseaseCancer-related costsCancer careBreast cancerMedian costSurvival rateEnd Results Program-MedicareFive-year survivalCancer care costsBreast surgerySurvival outcomesImproved outcomesOlder womenRadiation therapyCare costsStage IIDiseaseStudy periodWomenCancerCareSignificant national attentionOutcomesPercent
2014
Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011
Krumholz HM, Normand SL, Wang Y. Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011. Circulation 2014, 130: 966-975. PMID: 25135276, PMCID: PMC4171056, DOI: 10.1161/circulationaha.113.007787.Peer-Reviewed Original ResearchConceptsAcute cardiovascular diseaseCardiovascular diseaseIschemic strokeUnstable anginaHeart failureMyocardial infarctionNational Medicare dataYears of ageQuality of careDemographic subgroupsReadmission outcomesHospitalization ratesMortality overallService patientsCardiovascular conditionsAdjusted ratesHospitalizationMedicare dataMortality rateStrokeMortalityDiseaseAnginaReadmissionInfarction
2013
2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease
Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS. 2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease. Critical Pathways In Cardiology A Journal Of Evidence-Based Medicine 2013, 12: 65-105. PMID: 23680811, DOI: 10.1097/hpc.0b013e3182846e16.Peer-Reviewed Original Research2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease
Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS. 2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease. Circulation 2013, 127: 1052-1089. PMID: 23357718, DOI: 10.1161/cir.0b013e3182831a11.Peer-Reviewed Original Research
2012
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR, Smith SC, Spertus JA, Williams SV, Anderson JL. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Circulation 2012, 126: e354-e471. PMID: 23166211, DOI: 10.1161/cir.0b013e318277d6a0.Peer-Reviewed Original Research